PRE-Symptomatic Studies in Amyotrophic Lateral Sclerosis
NCT ID: NCT01508962
Last Updated: 2025-02-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
100 participants
OBSERVATIONAL
2013-11-30
2037-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study
NCT00317616
Clinical Procedures to Support Research in ALS
NCT03489278
Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS)
NCT00580593
PREVENT ALL ALS Study
NCT06581861
Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
NCT04454892
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy individuals (controls)
No interventions assigned to this group
Individuals affected with ALS (sporadic or familial)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is a male or female, aged at least 18 years.
* Subject is affected with ALS (familial or sporadic).
* Subject has at least one limb in which there is no symptomatic upper and lower motor neuron dysfunction.
* Subject is willing and able to comply with all study procedures.
* Subject agrees to provide signed and dated informed consent form.
Control group:
* Subject is a male or female, aged at least 18 years.
* Subject is not affected with ALS or an ALS-related disorder.
* Subject does not have a family history (i.e., at least 2 biological relatives) of ALS or an ALS-related disorder.
* Subject is willing and able to comply with all study procedures.
* Subject agrees to provide signed and dated informed consent form.
Exclusion Criterion
• Any condition or situation which, in the PI's opinion, could confound the biomarker data or may interfere significantly with the individual's participation and compliance with the study protocol, including but not limited to neurological, psychological and/or medical conditions (e.g., multiple sclerosis, neuropathy, myelopathy).
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Miami
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael Benatar
Professor of Neurology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Miami
Miami, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRESS-ALS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.